

FULL YEAR 2018 RESULTS

FULL YEAR 2018 SALES

\$81.6B	WORLDWIDE INCREASED ▲	Excluding acquisitions/ divestitures on an operational basis worldwide sales	INCREASED ▲
	6.7%		5.5%*

DILUTED EARNINGS PER SHARE

\$5.61

ADJUSTED DILUTED EARNINGS PER SHARE*

\$8.18 | INCREASED ▲ **12.1%**



Alex Gorsky
Chairman and
Chief Executive Officer
Johnson & Johnson

"Johnson & Johnson delivered another year of strong operational sales growth of 6.3% and achieved our 35th consecutive year of adjusted operational earnings growth at 9.8% in 2018. This can be attributed to accelerated underlying sales performance across each of our businesses, where we also leveraged our scale across the enterprise to improve margins. Looking ahead, the strength of our broad-based business and disciplined approach to portfolio management positions us to continue to fuel investments in innovation that enable us to capitalize on strategic opportunities and deliver strong performance over the long-term. Our performance is the result of our talented Johnson & Johnson colleagues and their extraordinary dedication to help advance health and well-being for patients and customers around the world."


WORLDWIDE CONSUMER SALES

\$13.9B Consumer worldwide sales increased: **1.8%**
Primary contributors to growth:



WORLDWIDE PHARMACEUTICAL SALES

\$40.7B Pharmaceutical worldwide sales increased: **12.4%**
Primary contributors to growth:



WORLDWIDE MEDICAL DEVICES SALES

\$27.0B Medical Devices worldwide sales increased: **1.5%**
Primary contributors to growth:



SURGICAL
VISION



ELECTROPHYSIOLOGY



ACUVUE®
CONTACT LENSES



BIOSURGERY



ENDOCUTTERS



WOUND
CLOSURE



ENERGY

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on January 22, 2019, available at <http://www.investor.jnj.com/sales-earnings.cfm>.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on January 22, 2019, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.